Apogee Therapeutics, Inc. (APGE) - Stock Analysis
Last updated: May 10, 2026
Research Idea
Research content for general circulation. Not individualized advice. Methodology & Disclosures
Apogee has multiple imminent clinical catalysts (APEX Phase 2 Part B 16‑week topline in Q2 2026 and Phase 3 AD start H2 2026) on top of strong 52‑week APEX Part A durability data released 2026‑03‑23 and a ~$350m equity raise at $70 that extends cash runway into 2028; with 21‑day ROC ~+10.8% and price ~9% above its 21‑day SMA, the setup is a classic event‑driven biotech hot idea.
Loading chart data...
AI Analyst Overview
Loading chart data...
Valuation Metrics
Fundamental Analysis
Key Financial Insights: • Cash Cushion • No Revenue • High Burn APGE has a very strong cash position and minimal debt, but the absence of revenue and heavy operating cash burn in 2025 drove substantial losses and leaves valuation dependent on future clinical progress.
Price Behavior
Key Price Behavior Insights: • Low-80s defense • Mid-80s resistance • Base failure risk Support Level: $80.75 / low-$80s Resistance Level: $84.50-$86.50 APGE is stabilizing after rebounding from $80.75, but it remains below the $84.50-$86.50 resistance band and needs to hold the low-$80s to avoid a trend break.
Sentiment & News
Key News Insights: • New High • Insider Sale • Analyst Targets Apogee Therapeutics hit a new 52-week high on analyst target updates, even as CEO Michael Thomas Henderson sold 20,000 shares, signaling strong momentum alongside insider selling.
AI Summary
APGE should now be viewed less as a cash-starved biotech and more as a well-capitalized clinical platform with runway into 2028, but the investment case still hinges on execution because heavy burn, dilution, and years-away commercialization mean the stock will only rerate if upcoming Phase 3 and comparative data clearly de-risk the pipeline.
Description
Apogee Therapeutics is a biotechnology firm developing biologic therapies for atopic dermatitis, COPD and related inflammatory and immunological conditions. Its lead programs are subcutaneously administered, extended half-life monoclonal antibodies advancing in AD and COPD, with additional earlier-stage antibody programs for AD. The company was founded in 2022 and is headquartered in Waltham, Massachusetts.
Idea History
| Date | Close | Ticker | Company | Summary | Status | P/L |
|---|---|---|---|---|---|---|
| Mar 26 | Apr 2 | APGE | Apogee Therapeutics, Inc. | Apogee has multiple imminent clinical catalysts (APEX Phase 2 Part B 16‑week topline in Q2 2026 and Phase 3 AD start H2 2026) on top of strong 52‑week APEX Part A durability data released 2026‑03‑23 and a ~$350m equity raise at $70 that extends cash runway into 2028; with 21‑day ROC ~+10.8% and price ~9% above its 21‑day SMA, the setup is a classic event‑driven biotech hot idea. | Closed | +7.5% |